Mendeleev Venture Investments invested 5.5 million rubles in the project of the Albogen company, which develops the PeptiGen drug design platform. The funds will be used to upgrade the composites portfolio and strengthen market positions. The investment company reported this to RB.RU.
The PeptiGen AI platform is designed to develop next-generation peptide compounds with different therapeutic effects.
According to Alexander Maslennikov, managing partner of Mendeleev Venture Investments, the use of AI in the pharmaceutical field has great potential for modern medicine.
Molecules generated by PeptiGen have successfully undergone in vitro experimental validation and laboratory animal testing. As a result of the research, eight promising antibiotics were patented.
As Albogen founder Albert Bolatchiev points out, the PeptiGen platform with a proprietary neural network is capable of generating molecules targeting the treatment of specific diseases with great precision. The technology also optimizes these elements to improve the therapeutic effect.
The platform generates particles with physical and chemical properties similar to those of natural peptides, which also increases their effectiveness.
Albogen will use the funds raised to expand its presence in the Russian and international markets.
The Albogen company was registered in 2022 and has since received three grants from the Skolkovo Foundation for a total of approximately 2.2 million rubles.
Author:
Natalia Gormaleva
Source: RB
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
